Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis

Lenalidomide and dexamethasone (Rd)-based triplets, in particular carfilzomib-Rd (KRd) and daratumumab-Rd (DaraRd), represent a standard of care in lenalidomide-sensitive multiple myeloma (MM) patients in first relapse. Meta-analysis of randomized clinical trials (RCT), suggested better outcome with...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Mangiacavalli, Silvia, Cartia, Claudio Salvatore, Galli, Monica, Pezzatti, Sara, Belotti, Angelo, Fazio, Francesca, Mina, Roberto, Marcatti, Magda, Cafro, Anna, Zambello, Renato, Paris, Laura, Barilà, Gregorio, Olivares, Cecilia, Pompa, Alessandra, Mazza, Rita, Farina, Francesca, Soldarini, Martina, Benvenuti, Pietro, Pagani, Giuseppina, Palumbo, Michele, Masoni, Valeria, Ferretti, Virginia Valeria, Klersy, Catherine, Arcaini1, Luca, Petrucci, Maria Teresa
Formaat: Online Artikel Texto
Taal:English
Gepubliceerd in: Fondazione Ferrata Storti 2022
Onderwerpen:
Article - Plasma Cell Disorders
Online toegang:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973473/
https://www.ncbi.nlm.nih.gov/pubmed/36200419
http://dx.doi.org/10.3324/haematol.2022.281342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973473/
https://www.ncbi.nlm.nih.gov/pubmed/36200419
http://dx.doi.org/10.3324/haematol.2022.281342

Gelijkaardige items